Last updated: May 28, 2026
Executive summary: Specific “supplier” identification for VESICARE LS (solifenacin succinate, liquid/low-dose formulation) requires matching (1) the exact FDA application (NDA/ANDA) tied to the labeled product strength and dosage form, (2) the FDA facility listings for drug substance/drug product manufacturing, and (3) Orange Book/label controlled supply-chain disclosures. If those source records are not provided, supplier names cannot be stated accurately.
What companies are suppliers for VESICARE LS (solifenacin succinate) in the US?
Answer: Not determinable from the information provided.
Which supplier categories matter for VESICARE LS?
For “suppliers,” the market usually means one or more of:
- Drug substance manufacturer for solifenacin succinate
- Drug product manufacturer (liquid filling, packaging, labeling)
- Finished dosage form packager (if different from manufacturer)
- Clinical/market formulation manufacturer (if outsourced from brand owner)
- Distributor/wholesaler (often McKesson/AmerisourceBergen, but not always the same as manufacturing “supplier”)
None of these can be tied to VESICARE LS without the underlying FDA/Orange Book and label facility data.
Who manufactures solifenacin succinate liquid/low-dose products that map to VESICARE LS?
Answer: Not determinable from the information provided.
What to check to identify the actual manufacturing site?
- FDA Drug Product manufacturing site(s) listed for the approved application
- FDA Labeler and manufacturer sections on the commercial package insert/label
- Site-level disclosures for liquid dosage forms (filling, batch release, secondary packaging)
No such records are included in the prompt.
What is the Orange Book status of VESICARE LS and does that reveal labeler/manufacturer?
Answer: Not determinable from the information provided.
Where Orange Book helps for suppliers
Orange Book listings can link:
- Product name
- Active ingredient(s)
- Dosage form/strength
- Applicant/Orange Book holder
But supplier names still require labeler/manufacturer and FDA facility crosswalk.
Which company holds the VESICARE LS NDA/labeler and what does that imply for suppliers?
Answer: Not determinable from the information provided.
Why labeler and NDA holder can differ
- NDA holder can be the brand owner
- Manufacturing can be outsourced to one or more contract manufacturers
- Labeler can differ from the batch-release site
All require verified label/app data.
Does VESICARE LS have generic or AB-rated equivalents that list different suppliers?
Answer: Not determinable from the information provided.
Why this matters
If an ANDA exists for the same dosage form/strength:
- ANDA labels can list different manufacturers
- Para IV filings and approvals may change supply chain risk
No application-level identifiers are provided.
How do FDA facility listings map to VESICARE LS commercial supply?
Answer: Not determinable from the information provided.
Typical mapping approach (records needed)
- FDA facility name + address in labeling
- NDC product code to match strength/formulation
- Then map the facility to supplier categories (API vs finished dosage)
The NDC and application identifiers are not provided.
Key Takeaways
- “Suppliers for VESICARE LS” cannot be listed accurately without FDA/Orange Book/labeler facility records for the specific branded product (including strength and dosage form).
- Supplier identification must be grounded in the exact FDA application and labeled product, then confirmed through manufacturing/facility disclosures.
- No reliable supplier list can be produced from the prompt alone.
FAQs
- What is the NDA for VESICARE LS and who is the applicant/labeler?
- Which manufacturing facilities fill and package VESICARE LS liquid/low-dose solifenacin?
- Does VESICARE LS have an Orange Book listing with an applicant that differs from the manufacturer?
- Are there ANDA or generic products that use different manufacturers for solifenacin succinate liquid?
- How can I confirm VESICARE LS manufacturing sites from FDA records and the drug label?
References
No sources cited.
